Medical Information
Saudi Arabia
 

This medical Information website is intended only for Healthcare Professionals in the Kingdom of Saudi Arabia. This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.

Please choose the category that best describes you.

This content is intended for Healthcare professionals in Saudi Arabia. Would you like to proceed?

I am a healthcare professional registered to practice in KSAYes, I am a healthcare professional registered to practice in KSA
SelectI am a healthcare professional registered to practice in KSAYes, I am a healthcare professional registered to practice in KSA
I am not a healthcare professionalNo, go back to the patient portal
SelectI am not a healthcare professionalNo, go back to the patient portal
Non-Saudi Arabia residents click here.

Congress Materials

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Poster
Jonathan I. Silverberg, Sonja Ständer, Jacob P. Thyssen, Brian S. Kim, Carla Castro, Anthony Bewley, Laurent Misery, Andrew G. Bushmakin, Joseph C. Cappelleri, Erman Guler, Justine Alderfer, Melisa Watkins, Gary Chan, Daniela E. Myers December 11, 2022 RAD Dec 2022 Atopic Dermatitis

Examining the Relationships Among Abrocitinib Treatment, Itch, Skin Pain, and Work and Activity Impairments in Patients With Atopic Dermatitis: A Mediation Modelling Analysis

View Presentation
Poster
Richard Gower, JinHua Xu, Maryam S. Alam, John C. Su, Daniela E. Myers, Paul Sanders, Bonnie Vlahos, Chuanbo Zang, Jar Lan, John Werth December 11, 2022 RAD Dec 2022 Atopic Dermatitis

Once-Daily Crisaborole as a Long-Term Maintenance Treatment in Participants With Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Trial

View Presentation
Poster
Eric L. Simpson, Jonathan I. Silverberg, Audrey Nosbaum, Kevin Winthrop, Emma Guttman-Yassky, Karin M. Hoffmeister, Alexander Egeberg, Hernan Valdez, Haiyun Fan, Saleem A. Farooqui, Gary Chan, Justine Alderfer, William Romero, Susan Johnson PO not an author: Sylvia Li December 11, 2022 RAD Dec 2022 Atopic Dermatitis

Safety of Abrocitinib in 3582 Patients With Moderate-to-Severe Atopic Dermatitis With Over 900 Patients Exposed for Almost 2 Years

View Presentation
Oral Presentation
Jonathan I. Silverberg, Eric L. Simpson, Jacob P. Thyssen, Andrew E. Pink, Stephan Weidinger, Gary Chan, Irina Lazariciu, Claire Clibborn, Erman Guler December 11, 2022 RAD Dec 2022 Atopic Dermatitis

Switching from Dupilumab to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis: An Analysis of Responders and Nonresponders to Dupilumab

View Presentation
Poster
Kristian Reich, Jonathan I. Silverberg, Marjolein de Bruin-Weller, Mette Deleuran, Lisa A. Beck, Kim Papp, Saleem A. Farooqui, Fan Zhang, Claire Feeney, Herwig Koppensteiner March 21, 2023 AAD 2023 Atopic Dermatitis

Abrocitinib Long-Term Efficacy for up to 96 Weeks in Patients With Moderate‑to‑Severe Atopic Dermatitis: Interim Analysis of JADE EXTEND, a Long-Term Extension Study

View Presentation
Poster
Jacob P. Thyssen, Jonathan I. Silverberg, Gil Yosipovitch, Shawn G. Kwatra, Jose-Manuel Carrascosa, Patrick M. Brunner, Irina Lazariciu, Claire Feeney, Francisco J. Rebollo, Herwig Koppensteiner March 21, 2023 AAD 2023 Atopic Dermatitis

Efficacy and Safety of Abrocitinib and Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis in the Presence or Absence of Comorbid Asthma or Allergic Rhinitis: A Post Hoc Pooled Analysis of JADE COMPARE and JADE DARE

View Presentation
Poster
Melinda Gooderham, Eric Simpson, Bob Geng, Linda F. Stein Gold, Andreas Wollenberg, Saleem A. Farooqui, Fan Zhang, Claire Feeney, Melissa Watkins, Herwig Koppensteiner March 21, 2023 AAD 2023 Atopic Dermatitis

Influence of Baseline Disease Severity Defined by Investigator’s Global Assessment on Abrocitinib Efficacy for up to 96 Weeks in Patients With Moderate‑to‑Severe Atopic Dermatitis: Interim Analysis of JADE EXTEND, a Long-Term Extension Study

View Presentation
Oral Presentation
Eric L. Simpson, Jonathan I. Silverberg, Audrey Nosbaum, Kevin Winthrop, Emma Guttman-Yassky, Alexander Egeberg, Haiyun Fan, Justine Alderfer, Susan Johnson, Saleem Farooqui March 21, 2023 AAD 2023 Atopic Dermatitis

Integrated Safety Analysis of Abrocitinib in 3802 Patients With Moderate-To-Severe Atopic Dermatitis With Over 5000 Patient-Years of Exposure

View Presentation
Poster
Jonathan I. Silverberg, Kristian Reich, Marjolein de Bruin-Weller, Mette Deleuran, Lisa A. Beck, Kim Papp, Saleem A. Farooqui, Fan Zhang, Claire Feeney, Melissa Watkins March 21, 2023 AAD 2023 Atopic Dermatitis

Response to Abrocitinib up to Week 96 According to Short-Term Response: A Post Hoc Analysis of the JADE-EXTEND Phase 3 Trial

View Presentation